top of page

No-Exam Term Life Insurance with Genital Herpes: Common Underwriting Questions

Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.

For many applicants, herpes is underwritten as part of the overall health profile rather than a standalone issue. Carriers may ask questions to confirm there's no related condition that changes risk.

  • Instant online pricing

  • No phone calls required

  • No pressure from agents

Usually a Disclosure Question, Not a "Dealbreaker"

How applications typically ask about STIs and history

Why carriers may ask about testing (including HIV) in some programs

How to keep quotes aligned with underwriting expectations

Herpes simplex virus type 2 (HSV-2) is a chronic viral condition, but its impact on life insurance underwriting is almost entirely determined by the applicant's overall health profile rather than the diagnosis in isolation. Underwriters are not applying a categorical exclusion for HSV-2 - they are assessing mortality risk, and a well-controlled, otherwise healthy applicant with HSV-2 is not carrying significantly elevated mortality risk from the diagnosis alone. The question underwriters are actually answering is whether there are any co-existing conditions, immunocompromising factors, or health complications that change that picture. Applicants who arrive at underwriting with a stable overall health profile tend to find the HSV-2 history is not the primary driver of their rate class or eligibility outcome.

Treatment approach can be a mild informational signal in the underwriting record. Antiviral therapy for HSV-2 generally falls into two patterns: episodic treatment, where the medication is taken only when an outbreak is detected or anticipated, and daily suppressive therapy, where the medication - typically acyclovir or valacyclovir - is taken continuously to reduce outbreak frequency and viral shedding. Daily suppressive therapy signals that outbreaks are frequent enough that the treating physician recommended continuous rather than as-needed management. Some underwriters note this distinction as context, though on its own it does not typically move the rate class - it becomes more relevant when combined with other health factors that together suggest a more complex overall profile.

The distinction between HSV-1 and HSV-2 can appear explicitly in underwriting instructions, and applicants sometimes encounter unexpected specificity in application question wording. HSV-1 - most commonly associated with oral herpes - is generally viewed differently in underwriting than HSV-2. Applications that ask specifically about HSV-2 or genital herpes as a separate line item do so because some programs categorize them differently based on transmission patterns and associated risk profiles. Reading each question carefully and answering exactly what is asked - neither volunteering information beyond what the question covers nor omitting what it directly asks about - is the correct approach and produces the most defensible application record when underwriting reviews it against the medical file.

HIV co-testing requirements are a separate underwriting protocol that sometimes creates confusion for applicants with HSV-2 in their history. Some carriers require HIV testing for all applicants above a certain coverage threshold as a standard protocol - this requirement is coverage-amount-driven and applies broadly to applicants at that tier, not specifically because of HSV-2 appearing on the application. The appearance of HIV testing requirements in the underwriting process does not mean the carrier suspects co-infection; it reflects that the program's testing requirements were triggered by the coverage level being requested. Applicants with HSV-2 who encounter this requirement should understand it in that context rather than treating it as a signal about how their HSV-2 history is being specifically evaluated.

The dominant underwriting factor for any applicant with HSV-2 is the overall health profile - stable immune function, no opportunistic infections, no immunocompromising medications such as chronic corticosteroids or biologics, and no co-existing conditions that would independently affect mortality risk. An applicant with HSV-2, normal lab values, no immunocompromising conditions, and a healthy weight and blood pressure profile is being evaluated primarily on those broader health factors rather than on the HSV-2 diagnosis itself. Consistent, accurate disclosure across all carriers being compared is the most practical protective step - inconsistencies in what different applications say about antiviral medication use, testing history, or outbreak frequency can create issues at the underwriting stage even when the underlying health profile is favorable and would otherwise support a standard rate class offer. Keeping your disclosures aligned across all applications ensures you are comparing real, apples-to-apples pricing rather than offers built on different assumptions.

For the full instant/no-exam term life guide and a clean overview of underwriting, see: https://www.careproinsurance.com/instant-term-life-insurance

General education only; does not replace professional advice in legal, tax, or medical areas. Quotes are estimates and final eligibility/pricing depend on underwriting, carrier guidelines, and the issued policy language.

Frequently Asked Questions

Can I get no-exam term life insurance if I have genital herpes?

Sometimes. Many applicants can qualify depending on the overall health profile and the carrier's guidelines. Underwriting review applies and rules vary by program.

Do I have to disclose herpes on a life insurance application?

You should answer the application questions honestly and exactly as written. Misstatements can cause the offer to change or create issues later.

Why do some carriers mention HIV testing in guidelines?

Some underwriting programs use different testing or documentation standards based on risk categories and coverage amount. Exact requirements vary by carrier and program.

Will herpes automatically increase my premium?

Not necessarily. Pricing is usually based on your overall health profile and underwriting class. Carrier guidelines vary, so shopping can help.

Will I need a medical exam because of herpes?

Not always. Some applicants qualify for accelerated/no-exam paths, but additional questions or documentation can be requested depending on the program and your full application.

What is the difference between episodic and suppressive antiviral therapy for HSV-2, and does it matter in underwriting?

Episodic therapy is taken only during outbreaks; suppressive therapy is taken daily to reduce outbreak frequency. Suppressive use can be a mild indicator that outbreaks are more frequent, but on its own it does not typically move the rate class. It becomes more relevant context when combined with other health factors.

Why do some carriers require HIV testing when HSV-2 appears on an application?

HIV testing requirements are generally coverage-amount-driven protocols, not triggered specifically by HSV-2. When they appear alongside an HSV-2 application, it typically means the coverage level crossed a threshold that triggers standard testing for all applicants in that program, not that the carrier is specifically screening because of the HSV-2 history.

Does HSV-1 versus HSV-2 distinction affect underwriting?

It can, depending on how the application question is worded. Some programs categorize HSV-1 and HSV-2 separately because of differences in transmission patterns and risk profiles. Reading each question carefully and answering exactly what is asked - for the specific virus type the question references - is the correct approach.

bottom of page